Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ENTA 
Enanta Pharmaceuticals Inc (ENTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ENTA (1-star) is a SELL. SELL since 4 days. Profits (3.18%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.67
1 Year Target Price $17.67
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.38% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 165.45M USD | Price to earnings Ratio - | 1Y Target Price 17.67 |
Price to earnings Ratio - | 1Y Target Price 17.67 | ||
Volume (30-day avg) 6 | Beta 0.88 | 52 Weeks Range 4.09 - 13.43 | Updated Date 08/15/2025 |
52 Weeks Range 4.09 - 13.43 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.84 | Actual -0.85 |
Profitability
Profit Margin -141.98% | Operating Margin (TTM) -103.16% |
Management Effectiveness
Return on Assets (TTM) -17.29% | Return on Equity (TTM) -80.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19404124 | Price to Sales(TTM) 2.55 |
Enterprise Value 19404124 | Price to Sales(TTM) 2.55 | ||
Enterprise Value to Revenue 0.3 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 21376600 | Shares Floating 14356152 |
Shares Outstanding 21376600 | Shares Floating 14356152 | ||
Percent Insiders 6.55 | Percent Institutions 85.21 |
Upturn AI SWOT
Enanta Pharmaceuticals Inc
Company Overview
History and Background
Enanta Pharmaceuticals, Inc. was founded in 1995. It is a biotechnology company focused on the research and development of small molecule drugs for viral infections and liver diseases.
Core Business Areas
- Viral Infections: Development of direct-acting antiviral (DAA) therapies for respiratory syncytial virus (RSV).
- Liver Diseases: Development of therapies for non-alcoholic steatohepatitis (NASH).
Leadership and Structure
The leadership team includes Jay R. Luly, Ph.D. (President and CEO). The company operates with a focus on research and development, with various departments responsible for drug discovery, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Glecaprevir (Partnered with AbbVie as part of Mavyret/Maviret): A protease inhibitor for Hepatitis C treatment. While Enanta received royalties from AbbVie's sales, the HCV market has declined. Competitors include Gilead Sciences.
- EDP-938 (RSV): An L-protein inhibitor in development for RSV. Currently in clinical trials. Competitors include GSK's Arexvy, Pfizer's Abrysvo and Moderna's mRNA RSV vaccine.
- EDP-514 (NASH): An oral FXR agonist in development for NASH. Currently in clinical trials. Competitors include Madrigal Pharmaceuticals.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The antiviral and liver disease segments are driven by unmet medical needs and aging populations.
Positioning
Enanta is a research-focused biotechnology company with a pipeline of novel drug candidates. Their expertise in small molecule drug discovery gives them a competitive advantage in developing therapies for viral infections and liver diseases.
Total Addressable Market (TAM)
The global market for RSV therapeutics is projected to reach billions of dollars. The NASH market is expected to be even larger, potentially exceeding $40 billion. Enanta is positioned to capture a portion of these markets with successful clinical development and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Strong expertise in small molecule drug discovery
- Proprietary drug development platform
- Experienced management team
- Partnership with AbbVie (historical revenue stream)
- Diversified pipeline with multiple clinical-stage programs
Weaknesses
- Dependence on successful clinical trial outcomes
- High research and development costs
- Limited commercialization capabilities (reliant on partnerships)
- Vulnerability to regulatory setbacks
- Diminished HCV royalty revenues
Opportunities
- Potential for breakthrough therapies in RSV and NASH
- Expansion of pipeline through strategic collaborations
- Out-licensing or partnering opportunities for drug candidates
- Favorable regulatory environment for innovative therapies
- Growing prevalence of NASH and RSV infections
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory delays or rejections
- Patent expirations
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- GILD
- MRVL
- JNJ
- GSK
- PFE
- MGLN
Competitive Landscape
Enanta's advantage lies in its focused research and development efforts. Its disadvantage is its smaller size and reliance on partnerships compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to royalty revenues from partnered HCV treatments. Future growth depends on success in RSV and NASH programs.
Future Projections: Consult analyst reports for revenue and earnings projections based on clinical trial outcomes and market potential.
Recent Initiatives: Focus on advancing EDP-938 (RSV) and EDP-514 (NASH) through clinical trials, as well as other compounds in their earlier stage pipeline.
Summary
Enanta Pharmaceuticals is a research-driven biotech company with expertise in developing small molecule drugs. Their historical reliance on HCV royalties has diminished, necessitating success in their RSV and NASH programs. Clinical trial outcomes represent a crucial factor for future growth. Their partnerships can be leveraged for resource efficiency, though large Pharma remains a threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Financial News Outlets (e.g., Yahoo Finance)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enanta Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2013-03-21 | President, CEO & Director Dr. Jay R. Luly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.enanta.com |
Full time employees 131 | Website https://www.enanta.com | ||
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.